Diamyd Medical AB (publ) - Asset Resilience Ratio

Latest as of May 2026: 9.77%

Diamyd Medical AB (publ) (DMYD-B) has an Asset Resilience Ratio of 9.77% as of May 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Diamyd Medical AB (publ)'s working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr39.73 Million

≈ $4.28 Million USD Cash + Short-term Investments

Total Assets

Skr406.63 Million

≈ $43.76 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Diamyd Medical AB (publ)'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Diamyd Medical AB (publ) asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Diamyd Medical AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Diamyd Medical AB (publ) (DMYD-B) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr39.73 Million	9.77%
Total Liquid Assets	Skr39.73 Million	9.77%

Asset Resilience Insights

Limited Liquidity: Diamyd Medical AB (publ) maintains only 9.77% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Diamyd Medical AB (publ) Industry Peers by Asset Resilience Ratio

Compare Diamyd Medical AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Diamyd Medical AB (publ) (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Diamyd Medical AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-08-31	78.60%	Skr277.19 Million ≈ $29.83 Million	Skr352.64 Million ≈ $37.95 Million	+17.62pp
2024-08-31	60.99%	Skr132.37 Million ≈ $14.24 Million	Skr217.04 Million ≈ $23.36 Million	-0.70pp
2023-08-31	61.69%	Skr126.96 Million ≈ $13.66 Million	Skr205.81 Million ≈ $22.15 Million	-5.82pp
2022-08-31	67.51%	Skr159.67 Million ≈ $17.18 Million	Skr236.52 Million ≈ $25.45 Million	-1.68pp
2021-08-31	69.19%	Skr139.38 Million ≈ $15.00 Million	Skr201.44 Million ≈ $21.68 Million	-6.97pp
2020-08-31	76.16%	Skr68.36 Million ≈ $7.36 Million	Skr89.76 Million ≈ $9.66 Million	-0.27pp
2019-08-31	76.43%	Skr56.71 Million ≈ $6.10 Million	Skr74.20 Million ≈ $7.99 Million	-3.80pp
2018-08-31	80.23%	Skr44.11 Million ≈ $4.75 Million	Skr54.98 Million ≈ $5.92 Million	-6.67pp
2017-08-31	86.90%	Skr85.72 Million ≈ $9.23 Million	Skr98.65 Million ≈ $10.62 Million	+3.79pp
2016-08-31	83.11%	Skr31.40 Million ≈ $3.38 Million	Skr37.78 Million ≈ $4.07 Million	+55.24pp
2015-08-31	27.87%	Skr13.00 Million ≈ $1.40 Million	Skr46.65 Million ≈ $5.02 Million	+6.39pp
2014-08-31	21.48%	Skr10.96 Million ≈ $1.18 Million	Skr51.02 Million ≈ $5.49 Million	-29.70pp
2012-08-31	51.18%	Skr215.85 Million ≈ $23.23 Million	Skr421.74 Million ≈ $45.39 Million	-2.29pp
2011-08-31	53.48%	Skr277.86 Million ≈ $29.90 Million	Skr519.60 Million ≈ $55.92 Million	--

pp = percentage points

About Diamyd Medical AB (publ)

ST:DMYD-B Sweden Biotechnology

Market Cap

$16.46 Million

Skr153.00 Million SEK

Market Cap Rank

#25803 Global

#523 in Sweden

Share Price

Skr1.01

Change (1 day)

+0.60%

52-Week Range

Skr1.00 - Skr17.62

All Time High

Skr71.00